Self-Adjuvating Lipid Nanoparticle mRNA Vaccine Elicits T-Cell Responses and Protects Against Immune Challenge

Log in to Add to My Schedule


Nucleic acid vaccines, DNA and messenger RNA (mRNA), have emerged as promising modalities for infectious disease and for cancer immunotherapy due, in part, to shortened manufacturing cycles and high potency. Currently, there is limited understanding of the mechanisms of antigen presentation and induction of specific T-Cell responses critical to long-term immunity. Lipid nanoparticles (LNP) composed of ionizable lipids are important components of such vaccines as they can convey and present the nucleic acid effectively to the immune system. Further improvements in LNP carriers require a reduction in the 1) systemic toxicity, 2) improved endosomal escape, 3) potent and T-cell specific adjuvating function and 4) targeting to specific antigen presenting cells. 

Here we report progress on the development of a biodegradable ionizable lipid based LNP (ssPalmE-LNP) and its application to DNA and mRNA vaccines.

Sponsored By